Introduction {#s1}
============

Eukaryotic flagella and cilia have essential roles in cell locomotion, fluid movement, and sensing. Their formation strictly requires the presence of centrioles, cylindrical organelles with a radially ninefold symmetric, peripheral microtubule array ([@bib6]; [@bib4]; [@bib23]). During ciliogenesis/flagellogenesis, centrioles (then referred to as basal bodies) dock to the cell membrane via their distal ends and nucleate the flagellar/ciliar axoneme from their microtubule array ([@bib48]; [@bib14]; [@bib29]; [@bib3]; [@bib10]). The symmetry and diameter of centrioles (and thereby of flagella/cilia) is, to a large extent, established through scaffolding by the centriolar cartwheel, a structure with a central ring-like hub and nine radially projecting spokes that contact the peripheral centriolar microtubules ([@bib4]; [@bib8]; [@bib23]).

The cartwheel is organized through the homo-oligomerization of the highly conserved centriolar protein SAS-6 ([@bib42]; [@bib32]; [@bib54]). High-resolution crystal structures of zebrafish and *C. reinhardtii* SAS-6 fragments together with biochemical and biophysical characterizations ([@bib32]; [@bib54]) demonstrated that two dimerization interfaces in SAS-6 mediate this oligomerization: a coiled-coil domain that forms a rod-like parallel dimer; and a globular N-terminal domain that forms a curved head-to-head dimer. Modeling these two dimer interactions together in silico resulted in ring assemblies that were compatible with the symmetry and dimension of cartwheels observed in vivo. In these models, the N-terminal head domains constitute the cartwheel hubs from which the coiled-coil rods project to form the cartwheel spokes ([@bib32]; [@bib54]). However, so far, no high-resolution structure of the SAS-6 cartwheel is available. Although rotary shadowing EM studies suggested that SAS-6 might be able to form cartwheels, the available resolution was insufficient to determine the symmetry of the observed assemblies directly ([@bib32]). Another, higher resolution, EM study with recombinant SAS-6 revealed cartwheel-like assemblies with an eightfold, not a ninefold symmetry ([@bib54]), while a third EM study showed the presence of SAS-6 tetramers ([@bib24]). Furthermore, the available biochemical and biophysical data do not provide evidence for efficient cartwheel formation by SAS-6 in solution ([@bib24]; [@bib32]; [@bib54]), raising the question of whether SAS-6 alone is sufficient to organize ninefold symmetric cartwheels and, if so, under what conditions.

SAS-6 is a highly conserved protein that is found in all eukaryotes that have cilia/flagella during some of their life-cycle stages ([@bib9]; [@bib28]). Inhibiting SAS-6 self-assembly by point mutations in vivo abolishes the formation of centrioles ([@bib32]; [@bib54]; [@bib37]) and thereby flagella ([@bib54]). Thus, targeting SAS-6 oligomerization by inhibitors could be a strategy to disable flagellogenesis in organisms that cause human disease and rely on flagella for their pathogenicity. The Trypanosomatids are of special interest in this respect. They consist of parasitic, eukaryotic protozoa with a single flagellum and comprise members that cause major human diseases, such as sleeping sickness (*Trypanosoma brucei*), Chagas disease (*Trypanosoma cruzi*), and Leishmaniasis (*Leishmania spec.*) ([@bib49]). These organisms display complex life cycles in which they shuttle between an insect vector and human or animal hosts. Their flagellum provides key roles in this life cycle through its multiple functions in essential cellular processes such as motility, signalling, sensing, and attachment ([@bib55]; [@bib46]; [@bib22]). Furthermore, the flagellar pocket, a membrane invagination from which the flagellum emerges, is the exclusive site of vesicular membrane traffic in these organisms ([@bib44]; [@bib35]; [@bib20], [@bib21]; [@bib43]). It is therefore not surprising that flagella have been demonstrated or are proposed to be key factors in the pathogenicity of these organisms ([@bib55]; [@bib46]; [@bib22]).

As in other eukaryotes, the flagellum of the Trypanosomatids is templated from centrioles (basal bodies). Tomographic EM studies demonstrated the presence of canonical, ninefold symmetric cartwheel structures in the centre of their centrioles ([@bib34]). Currently, no high-resolution structures of SAS-6 homologues from Trypanosomatids are available, and it is unclear whether oligomerization of their SAS-6 homologues could be inhibited.

Results {#s2}
=======

*Leishmania major* SAS-6 is highly similar to other SAS-6 homologues {#s2-1}
--------------------------------------------------------------------

The genomes of *Trypanosoma brucei*, *Trypanosoma cruzi*, and *Leishmania major* have recently been sequenced ([@bib5]; [@bib16]; [@bib30]). BLAST searches identified the likely SAS-6 homologues in these organisms with similar domain architectures ([Figure 1A](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}) and sequence identities to human SAS-6 of 21.0 ± 1.4% in 459 ± 21 aligned residues. Multiple sequence alignment of their N-terminal domains ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}) shows that key residues are well conserved compared to zebrafish SAS-6, the closest homologue of human SAS-6 for which high-resolution structures are available ([@bib54]). Different from zebrafish SAS-6, they have long N-terminal extensions ([Figure 1A](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1A,B](#fig1s1){ref-type="fig"}) that vary in length and are poorly conserved. Since these extensions hindered our crystallization attempts, we largely removed them in the constructs used in this manuscript. The part of the extensions still present did not show electron density in our crystal structures.10.7554/eLife.01812.003Figure 1.Structural and biophysical characterization of *L. major* SAS-6.(**A**) Domain overview of *L. major* SAS-6. Lines indicate constructs that were used in this work. (**B** and **C**) Left: ribbon presentation of the head-to-head dimers of *L. major* SAS-6's N-terminal domain present in the SAS-6^97--274^ crystal. Shown are the dimers formed between chain B and chain C (**B**) and chain A and symmetry-related chain A (**C**). α-helices (α) and β-sheets (β) are numbered sequentially. Right: detailed views of the corresponding dimerization interfaces. Interface residues are labelled and shown in sticks, dotted orange lines indicate hydrogen bonds. The two dimers show largely identical side-chain orientations in their interfaces. Note, however, that F257 (ringed in blue) in the B--C dimer inserts into a hydrophobic pocket, while in the A--A dimer Y215 is flipped into this pocket and displaces F257. To better illustrate this, a semi-transparent molecular surface of one of the subunits is also presented (grey). (**D**) Sedimentation-equilibrium analytical ultracentrifugation data for 400 µM *L. major* SAS-6^97--274^ wild-type (blue circles) and F257E mutant (green circles) and Y215K mutant (red circles) obtained at 11300, 17000, and 21200 rpm. Data for the F257E mutant were fitted to an ideal single-species model (solid line). Analysis of multiple concentrations gave a molecular weight of 17,727 ± 219 Da, close to the expected molecular weight for the monomer of 19,640 Da. As initial fits to a similar model for the WT and Y215K data gave higher molecular weights of 27,589 ± 209 Da and 30,951 ± 595 respectively, the data were fitted to a monomer--dimer equilibrium model (solid line) giving dissociation constants, K~D~, of 622 ± 70 µM for the WT and 190 ± 27 µM for Y215K mutant. The plots on the right show the residuals of the fits to the data for the wild-type (blue circles) and the corresponding F257E mutant (green circles) and Y215K mutant (red circles). (**E**) Left: ribbon presentation of the *L. major* SAS-6^97--320^ F257E coiled-coil dimer structure (chain A: red, chain B: green). Right: detailed view of the region boxed on the left. Interaction interface between N-terminal head domain and the coiled-coil stalk. Residues that make contact are labelled and are shown as sticks, dotted orange lines indicate hydrogen bonds.**DOI:** [http://dx.doi.org/10.7554/eLife.01812.003](10.7554/eLife.01812.003)10.7554/eLife.01812.004Figure 1---figure supplement 1.*L. major* SAS-6 and *Danio rerio* SAS-6 are highly similar.(**A**) Schematic representation of *Leishmania major* and *Danio rerio* SAS-6. Both proteins show a similar overall architecture with an N-terminal head domain and a coiled-coil domain of comparable lengths. The bar indicates the aligned SAS-6 region shown in (**B**). (**B**) Multiple sequence alignment of the N-terminal head domains of SAS-6 from *Trypanosoma brucei*, *Trypanosoma cruzi*, *Leishmania major*, and *Danio rerio*. The numbering refers to *L. major* SAS-6. The alignment is colored according to the Clustal coloring scheme. Red stars indicate key residues of the interaction interface of the homo-dimer of this domain. (**C**) Overlay of the structures of *L. major* SAS-6^97--274^ (green) and *Danio rerio* N-SAS-6^1--156^ (blue). Face-on view onto the hydrophobic pocket into which a highly conserved phenylalanine (F257 in *L. major*, F131 in *D. rerio* SAS-6) is inserted in the homo-dimerized form of this domain. Residues of this pocket are labelled and are shown as sticks. (**D**) Detailed view of the interaction interface between N-terminal head domain and the coiled-coil stalk of SAS-6. Overlay of this interface from *L. major* SAS-6^97--320^ F257E (green) with that from *Danio rerio* N-SAS-6^1--179^ F131D (blue). Residues that make contact are labelled and are shown as sticks, dotted yellow lines indicate hydrogen bonds.**DOI:** [http://dx.doi.org/10.7554/eLife.01812.004](10.7554/eLife.01812.004)10.7554/eLife.01812.005Figure 1---figure supplement 2.The closed Y215 conformation is observed in the low affinity head-to-head homo-dimer of the F257E mutant.(**A**) Ribbon presentation of the SAS-6 octamer present in the *L. major* SAS-6^97--320^ F257E crystal. The ASU of the crystal contained four SAS-6 monomers that are labelled from A--D. The arrow specifies the view direction shown as a close-up in (**B**). (**B**) Left: ribbon presentation of the B--C head-to-head homo-dimer in the *L. major* SAS-6^97--320^ F257E crystal. Right: corresponding detailed view of the homo-dimer interface. The other head-to-head dimers in the crystal showed similar arrangements to the ones presented here. Interface residues are labelled and shown in sticks. Dotted yellow lines indicate hydrogen bonds. Highlighted in lemon and ringed in blue is the mutated E257 residue. Note that Y215 is swung into the hydrophobic pocket, whereas E257 points outwards. The remainder of the interface residues show similar side-chain orientations as observed in the wild-type SAS-6^97--274^ crystal ([Figure 1](#fig1){ref-type="fig"}).**DOI:** [http://dx.doi.org/10.7554/eLife.01812.005](10.7554/eLife.01812.005)

To elucidate the structural organization of *L. major* SAS-6, we solved the structure of its N-terminal domain (Lm SAS-6^97--274^) by X-ray crystallography to a resolution of 2.2 Å ([Table 1](#tbl1){ref-type="table"}, [Table 2](#tbl2){ref-type="table"}; [Figure 1B](#fig1){ref-type="fig"}). The asymmetric unit (ASU) of the crystal contained three molecules that were virtually identical to each other (139 ± 2 selected pairs superpose with an rmsd of 0.70 ± 0.13 Å in secondary structure matching). Our structure demonstrates a high similarity of *L. major* SAS-6 to previously solved SAS-6 structures ([@bib32]; [@bib54]) (secondary structure matching to the *D. rerio* SAS-6 head domain results in an rmsd of 1.59 ± 0.09 Å with 133 ± 2 selected pairs). Like these, the N-terminal domain of *L. major* SAS-6 consists of a 7-stranded β-barrel, capped by a helix-turn-helix motif, that forms a curved cross-handshake homo-dimer within the crystal through a highly conserved interaction interface ([Figure 1B](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1B,C](#fig1s1){ref-type="fig"}). In this dimer, the β-hairpins formed by β-strands β6 and β7 pack antiparallelly against each other. Phenylalanine 257 at the tip of this hairpin is inserted into a conserved hydrophobic pocket that is constituted by the helix-turn-helix motif and the base of this hairpin in the B-C homo-dimer (formed by chain B and chain C in the crystal, [Figure 1B](#fig1){ref-type="fig"}). Dimerization is also observed in solution, as judged by equilibrium ultracentrifugation, and then depends on the presence of F257 ([Figure 1D](#fig1){ref-type="fig"}). The measured K~D~ of this dimerization is ∼600 μM and therefore approximately 5- to 10-fold weaker than seen for other SAS-6 homologues ([@bib32]; [@bib54]).10.7554/eLife.01812.006Table 1.Native dataset analysis and refinement statistics**DOI:** [http://dx.doi.org/10.7554/eLife.01812.006](10.7554/eLife.01812.006)*L. major* SAS-6^97--274^ WT*L. major* SAS-6^97--320^ F257E*L. major* SAS-6^97--320^ WTBeamlineDiamond I04ESRF ID29ESRF BM14Space GroupP43212C121H3Wavelength (Å)0.97940.900.97813Monomers in the asymmetric unit346Unit Cell dimensions (Å)a = 84.25 b = 84.25 c = 239.94 α = 90.0 β = 90.0 γ = 90.0a = 108.9 b = 81.25 c = 133.1 α = 90.0 β = 91.5 γ = 90.0a = 482.7 b = 482.7 c = 43.13 α = 90.0 β = 90.0 γ = 120.0Resolution (Å)48.9--2.246.91--2.9/3.4 (anisotropy)66.9--3.5/4.2 (anisotropy)Completeness (overall/inner/outer shell)99.9/98.9/10099.9/99.1/99.9100/99.1/100Rmerge (overall/inner/outer shell)0.144/0.064/1.5050.152/0.032/2.5700.335/0.074/3.061Rpim (overall/inner/outer shell)0.065/0.030/0.6570.061/0.013/1.0330.073/0.016/0.704Mean I/σI (overall/inner/outer shell)7.6/18.6/1.410.6/41.4/0.98.2/33.3/1.5Multiplicity (overall/inner/outer shell)5.9/5.5/6.07.2/6.7/7.122.3/21.9/19.8Number of reflections45,56924,09048,521Number of atoms353656538777Waters14100Rwork/Rfree (% data used)20.8/24.5 (5.0%)23.7/25.6 (5.0%)22.4/24.2 (5.1%)rmsd from ideal values: bond length/angles0.010/1.3490.008/1.2550.006/1.348Mean B value51.592.8150.6Average Real-space correlation coefficient0.9760.9240.881Molprobity Score1.14 (100^th^ percentile)1.33 (100^th^ percentile)1.41 (100^th^ percentile)10.7554/eLife.01812.007Table 2.SeMet *L. major* SAS-6^97−274^ WT dataset analysis**DOI:** [http://dx.doi.org/10.7554/eLife.01812.007](10.7554/eLife.01812.007)BeamlineDiamond I03Space groupP43212Wavelength (Å)0.9794 (Peak)0.9796 (Inflection)0.9393 (Remote)Unit Cell dimensions (Å)a = 84.19 b = 84.19 c = 239.6 α = 90.0 β = 90.0 γ = 90.0a = 84.24 b = 84.24 c = 239.7 α = 90.0 β = 90.0 γ = 90.0a = 84.22 b = 84.22 c = 239.7 α = 90.0 β = 90.0 γ = 90.0Resolution (Å)68.9--2.368.9--2.368.9--2.3Completeness (overall/inner/outer shell)99.8/99.9/99.799.7/99.9/99.799.8/99.7/99.7Rmerge (overall/inner/outer shell)0.130/0.066/0.9420.122/0.048/1.0010.131/0.052/0.973Rpim (overall/inner/outer shell)0.066/0.036/0.4670.062/0.026/0.4970.066/0.028/0.486Mean I/sd(I) (overall/inner/outer shell)7.4/18.8/1.77.8/21.8/1.77.2/20.2/1.6Multiplicity (overall/inner/outer shell)4.8/4.1/4.94.7/4.1/4.94.7/4.0/4.8Se sites found/expected14/12

To ascertain the role of the coiled-coil domain of *L. major* SAS-6, we tried to crystallize constructs that included both the N-terminal domain and parts of the coiled-coiled domain, but initially failed to obtain diffraction-grade crystals. However, by introducing the F257E mutation to strongly weaken head-to-head dimerization we managed to crystallize construct Lm SAS-6^97--320^ F257E that contained the N-terminal head domain and the first seven heptad-repeats of the coiled-coil domain. We subsequently solved its X-ray structure to a resolution of 2.9 Å ([Table 1](#tbl1){ref-type="table"}; [Figure 1E](#fig1){ref-type="fig"}). The asymmetric unit of the crystal contained four molecules that were highly similar to each other and superposed with an rmsd of 1.17 ± 0.50 Å in secondary structure matching with 165 ± 16 selected pairs. The crystal structure revealed that the *L. major* SAS-6 coiled-coil domain is a parallel dimer and packs via conserved interactions against the N-terminal head-domains as seen in other SAS-6 homologues ([Figure 1E](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}). Thus, our structural analyses demonstrate that *L. major* SAS-6 is highly similar to other SAS-6 homologues.

Alternative dimerization arrangements of *Leishmania major* SAS-6 reveal a dimerization-impaired state {#s2-2}
------------------------------------------------------------------------------------------------------

Our structural analysis also revealed the presence of an alternative arrangement of the head-to-head homo-dimer of *L. major* SAS-6. In the Lm SAS-6^97--274^ crystal, the A--A homo-dimer (formed by chain A and symmetry-related chain A) shares the features of the B--C homo-dimer described above. However, in the A--A homo-dimer, the Y215 sidechain is flipped into its own hydrophobic pocket resulting in the displacement from this pocket of residue F257 of its homo-dimer partner ([Figure 1C](#fig1){ref-type="fig"}) probably weakening the interaction. Intriguingly, we found a similar arrangement in the Lm SAS-6^97--320^ F257E crystal. The F257E mutation abolishes head-to-head dimerization in solution ([Figure 1D](#fig1){ref-type="fig"}), yet, in the crystal, due to the high protein and precipitant concentrations, some of the SAS-6 molecules present are found nevertheless in head-to-head dimers and form a curved octamer. In this octamer residues Y215 are also swung into their own hydrophobic pockets, while E257 point away from them ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). These data suggest that the closed Y215 conformation corresponds to a low-affinity dimerization state of the head domains and might therefore constitute a potential regulatory mechanism of SAS-6 oligomerization. In solution, the presence of a dimerization-impaired state could also explain the relatively low affinity of head-to-head dimerization of wild-type *L. major* SAS-6 apparent in analytical ultracentrifugation (∼600 μM compared to 50--100 μM observed for other species) since other SAS-6 homologues do not have aromatic residues at the equivalent position of Y215 that could play such a role.

To test whether the Y215 closed conformation significantly compromises dimerization in solution, we mutated Y215 in Lm SAS-6^97--274^ to lysine that is unable to block the hydrophobic pocket in a similar way. Subsequently, we subjected the purified protein to analytical ultracentrifugation ([Figure 1D](#fig1){ref-type="fig"}). The measured K~D~ of head-to-head dimerization of the Y215K mutant was ∼200 μM and therefore approximately threefold lower than for the corresponding wild-type protein. We conclude that Y215 acts to partially inhibit head-to-head dimerization of *L. major* SAS-6.

*Leishmania major* SAS-6 crystallizes as ninefold symmetric rings that are highly similar to centriolar cartwheels in vivo {#s2-3}
--------------------------------------------------------------------------------------------------------------------------

The presence of curved SAS-6 octamers in the crystal of the Lm SAS-6^97--320^ F257E mutant that is strongly impaired in its ability to form head-to-head dimers suggests that wild-type versions of SAS-6 would adopt even larger assemblies. The low affinity of head-to-head dimerization together with the concomitant sample heterogeneity makes EM studies of the resulting assemblies technically challenging. To overcome these limitations we tried to crystallize *L. major* SAS-6 constructs with both dimerization interfaces intact. Obtaining crystals that diffracted well enough to solve their structure proved difficult. However, with the wild-type construct of Lm SAS-6^97--320^, we finally succeeded to find a crystal form of the space-group H3 that diffracted to a resolution of ∼3.5 Å along the l-axis with anisotropy limiting the resolution along the h-k plane to ∼4.2 Å. Using the structure of the Lm SAS-6^97--274^ B--C homo-dimer as a search model, a molecular replacement solution could be found that allowed the subsequent placement of the coiled-coil part present in the construct ([Figure 2](#fig2){ref-type="fig"}). The unit cell of the Lm SAS-6^97--320^ crystal form contained three 9-fold symmetric SAS-6 rings with three SAS-6 dimers constituting the ASU. These three dimers were highly similar to each other and overlayed with an rmsd of 0.88 ± 0.29 Å in secondary structure matching with 357 ± 14 selected pairs. No electron density was seen inside the SAS-6 rings. The inner diameters of the SAS-6 rings are ∼19 nm and correspond well to the diameters of cartwheel hubs observed in vivo ([@bib34]; [@bib25], [@bib26]). In the crystal, SAS-6 rings are stacked onto each other. Neighbouring rings interact through inter-digitation of their coiled-coil domains in an antiparallel way ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). We confirmed our structural model by calculating a phased anomalous map using the refined phases based on our model and the amplitudes of an isomorphic dataset collected from crystals of the selenomethionine derivative ([Figure 2B](#fig2){ref-type="fig"}; [Table 3](#tbl3){ref-type="table"}). Peaks in this map correlated with the positions of methionines in our model. Thus, under appropriate conditions, *L. major* SAS-6 can adopt ninefold symmetric rings that are highly similar to cartwheels observed in vivo.10.7554/eLife.01812.008Figure 2.*L. major* SAS-6^97--320^ crystallizes as a ninefold symmetric ring with dimensions similar to those of centriolar cartwheels observed in vivo.(**A**) Ribbon presentation of the *L. major* SAS-6^97--320^ structure. Shown is the ring assembly present in the unit cell of the *L. major* SAS-6^97--320^ crystal. Protein chains are colored alternatingly in green and red to allow easier comparison with [Figure 1](#fig1){ref-type="fig"}. Top: side-view, bottom: face-on view of the *L. major* SAS-6^97--320^ ring structure. The nonagon in the center of the ring indicates the (quasi-) ninefold symmetry axis. The ASU of the crystal contained six SAS-6 monomers that are labelled from A--F. No clear electron density could be seen for the distal part of the coiled-coil of the A--B dimer, probably due to the lack of stabilizing crystal packing interactions compared to the C--D and E--F dimer ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). (**B**) Detailed view of the region boxed in (**A**). Shown in blue sticks are the methionine-side chains of the SAS-6^97--320^ model. In magenta, iso-mesh representation of the phased anomalous difference map at a contour level of σ = 5 showing the selenium positions in the crystallized selenomethionine derivate of *L. major* SAS-6^97--320^.**DOI:** [http://dx.doi.org/10.7554/eLife.01812.008](10.7554/eLife.01812.008)10.7554/eLife.01812.009Figure 2---figure supplement 1.The crystal packing interactions observed in the *wild-type L. major* SAS-6^97--320^ crystal.(**A**) Stacking of the *L. major* SAS-6^97--320^ rings in the crystal. Rings are stacked directly onto each other through interactions of the N-terminal domains of SAS-6. Left: face-on view, right: turned by 90° around the x-axis. (**B**) Lateral interactions of the *L. major* SAS-6^97--320^ rings in the crystal. Top: face-on view, the arrow indicates the view direction shown at the bottom as a close-up. The coiled-coil stalks interact in an antiparallel way with each other. Their termini touch the head domains of adjacent rings.**DOI:** [http://dx.doi.org/10.7554/eLife.01812.009](10.7554/eLife.01812.009)10.7554/eLife.01812.010Figure 2---figure supplement 2.The interfaces critical for ring formation in the *wild-type L. major* SAS-6^97--320^ crystal are similar in orientation to those observed in the SAS-6^97--320^ F257E and the SAS-6^97--274^ crystals.(**A**) Overlay of the wild-type *L. major* SAS-6^97--320^ ring structure (green) with the two dimers present in the ASU of the *L. major* SAS-6^97--320^ F257E crystal (A--B dimer in magenta, C--D dimer in red). The SAS-6^97--320^ F257E A--B/C--D dimer superposed to wild-type *L. major* SAS-6^97--320^ with an rmsd of 0.91 Å/1.62 Å in secondary structure matching with 330/319 selected pairs respectively. (**B**) Overlay of the wild-type *L. major* SAS-6^97--320^ ring structure (green) with the B--C dimer present in the ASU of the *L. major* SAS-6^97--274^ crystal (blue). Secondary structure matching of these two structures resulted in an rmsd of 0.77 Å (283 selected pairs).**DOI:** [http://dx.doi.org/10.7554/eLife.01812.010](10.7554/eLife.01812.010)10.7554/eLife.01812.011Table 3.SeMet *L. major* SAS-6^97−320^ WT dataset analysis**DOI:** [http://dx.doi.org/10.7554/eLife.01812.011](10.7554/eLife.01812.011)BeamlineESRF BM14Space groupH3Wavelength (Å)0.97872 (Peak)Unit Cell dimensions (Å)a = 481.7 b = 481.7 c = 42.9 α = 90.0 β = 90.0 γ = 120.0Resolution (Å)48.2--4.0/5.4 (anisotropy)Completeness (overall/inner/outer shell)100.0/98.8/100.0Rmerge (overall/inner/outer shell)0.194/0.054/2.118Rpim (overall/inner/outer shell)0.091/0.026/0.987Mean I/sd(I) (overall/inner/outer shell)3.8/13.7/0.9Multiplicity (overall/inner/outer shell)5.6/5.5/5.6

A small compound can inhibit SAS-6 oligomerization in vitro {#s2-4}
-----------------------------------------------------------

To find out whether we could inhibit SAS-6 oligomerization, we conducted a small-scale fragment screen using a custom library of halogenated fragments (HEFLib) ([@bib57]). First, pools of compounds were screened for their ability to bind to and thereby cause a shift perturbation in the {^1^H,^15^N}-HSQC NMR spectrum of ^15^N labelled Lm SAS-6. To avoid ambiguities in the interpretation of shift perturbations that could stem from the partial presence of oligomers, we used the Lm SAS-6^97--274^ F257E mutant for these binding studies that is monomeric in solution ([Figure 1D](#fig1){ref-type="fig"}). One dimensional spin-echo experiments provided a crude estimate of 18 ms for the backbone amide ^1^H *T*~2~ relaxation time constants, consistent with the molecular mass of the construct (∼20 kDa) ([@bib2]).

To determine the putative interaction sites of binding candidates, we assigned the backbone resonances of Lm SAS-6^97--274^ F257E using ^13^C,^15^N double-labelled protein and mapped the HSQC chemical shift perturbations onto the crystal structure of wild-type Lm SAS-6^97--274^. Strong perturbations in chemical shifts are most consistent with compound PK9119 ((5-bromo-7-ethyl-1*H*-indol-3-ylmethyl)-dimethyl-amine, [Figure 3A](#fig3){ref-type="fig"}) binding adjacent to the head-to-head dimerization interface of Lm SAS-6^97--274^ ([Figure 3B](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1A,B](#fig3s1){ref-type="fig"}). Smaller, but significant shift changes indicate that binding may alter this interface by affecting the conformation of the helix-turn-helix motif that constitutes a part of it. We also examined aromatic side chain ^1^H resonances of the Phe and Tyr residues using Cβ--Hδ correlation maps, which enabled us to identify two side-chains (F199, F212) that are perturbed on binding of PK9119 ([Figure 3B](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}). These two side-chains cluster together around the helix-turn-helix motif. HSQC chemical shift titration experiments with PK9119 and *L. major* SAS-6^97--274^ F257E suggest a millimolar binding affinity; the low solubility of PK9119 in aqueous solutions and lack of a reference compound for competition binding assays makes more accurate K~D~ determinations technically challenging.10.7554/eLife.01812.012Figure 3.A small chemical compound can inhibit SAS-6 oligomerization.(**A**) The chemical structure of compound PK9119 as a structure formula (top) or three-dimensional model (bottom). (**B**) Heat map of the chemical shift perturbations in the {^1^H-^15^N}-HSQC spectrum of ^15^N-labelled *L. major* SAS-6^97--274^ F257E in the presence of 2 mM PK9119. Data are plotted onto the crystal structure of wild-type *L. major* SAS-6^97--274^. Higher shift perturbation is depicted in warmer colors, whilst prolines (not observable in the HSQC) are colored grey, and unassigned/untraced residues are colored white. The magenta F257 is from the homo-dimer partner and is inserted into the hydrophobic pocket of the dimerization interface. Note that the chemical shift perturbations cluster close to this pocket. Side-chains are drawn for F199 and F212 that showed robust perturbations in (HB)CB(CGCD)HD correlation spectra in the presence of 1 mM PK9119 ([Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}). (**C**) SEC-MALS chromatogram of *L. major* SAS-6^97--424^ showing the refractive index signal with the derived molar masses indicated by the thicker horizontal lines. *L. major* SAS-6^97--424^ displayed a distribution of masses from that of the dimer up to \>200 kDa consistent with a concentration driven self-association equilibrium. In the presence of 1 mM PK9119 the maximal mass was almost halved. The F257E mutant displayed a constant mass of 71 kDa in the absence and presence of PK9119 consistent with the mass of a dimer of *L. major* SAS-6^97--424^. All samples were injected on SEC-MALS at 25 mg/ml (675 μM in monomer). Due to dilution during SEC the peak concentrations achieved were a factor of ∼10 lower than this (∼68 μM in monomer).**DOI:** [http://dx.doi.org/10.7554/eLife.01812.012](10.7554/eLife.01812.012)10.7554/eLife.01812.013Figure 3---figure supplement 1.Chemical shift perturbation of SAS-6 by PK9119.(**A**) {^1^H-^15^N}-HSQC overlay of ^15^N-labelled *L. major* SAS-6^97--274^ F257E in the presence or absence of 1 mM or 2 mM PK9119. (**B**) Graphical representation of the chemical shift perturbations from the data in panel **A**, 2 mM PK9119. Perturbation is quantified as a weighted combination Δδ^1^H + (Δδ^15^N/5). The blue line indicates that the trajectory of the S170 correlation is not quantified, as its peak could not be traced in the presence of PK9119. (**C**) Overlay of (HB)CB(CGCD)HD spectra for 13C/^15^N labelled protein in the presence or absence of 1 mM PK9119, showing Cβ--Hδ correlations for Phe and Tyr side chain resonances. Cβ resonance frequencies of three unperturbed correlations (F184, F185 and Y230), indicated by a horizontal line, are unresolved to within the 0.2 ppm/point resolution of the Cβ assignment spectra, and are not assigned.**DOI:** [http://dx.doi.org/10.7554/eLife.01812.013](10.7554/eLife.01812.013)10.7554/eLife.01812.014Figure 3---figure supplement 2.PK9119 affects the oligomerization of zebrafish SAS-6.SEC-MALS chromatogram of *Danio rerio* SAS-6^1--326^ showing the refractive index signal with the derived molar masses indicated by the thicker horizontal lines. Dr SAS-6^1--326^ displayed a distribution of masses from that of the dimer up to ∼250 kDa consistent with a concentration driven self-association equilibrium. In the presence of 1 mM PK9119, the maximal observed mass was reduced to ∼160 kDa. The F131D mutant displayed a constant mass of 75 kDa in the absence and presence of PK9119 consistent with the mass of a Dr SAS-6^1--326^ dimer. All samples were injected on SEC-MALS at 10 mg/ml (263 μM in monomer). Due to dilution during SEC, the peak concentrations were a factor of ∼10 lower than this (∼26 μM in monomer). The largest species seen for Dr SAS-6^1--326^ are bigger than seen for *L. major* SAS-6^97--424^ ([Figure 3C](#fig3){ref-type="fig"}), despite a threefold lower concentration in monomer. This observation is consistent with the weaker head-to-head dimerization K~D~ for *L. major* SAS-6 seen by analytical ultracentrifugation when compared with measurements on *D. rerio* SAS-6 ([@bib54]).**DOI:** [http://dx.doi.org/10.7554/eLife.01812.014](10.7554/eLife.01812.014)

To determine whether PK9119 affects oligomerization of *L. major* SAS-6, we subjected wild-type and F257E mutant protein to size-exclusion chromatography---multi-angle light scattering (SEC-MALS) in the presence or absence of 1 mM PK9119 ([Figure 3C](#fig3){ref-type="fig"}). Since we were unable to make full length *L. major* SAS-6 recombinantly, we used a *L. major* SAS-6 construct that contained the N-terminal domain and approximately half of its coiled-coil domain (Lm SAS-6^97--424^) for this assay. Similar to the previous findings ([@bib24]; [@bib32]; [@bib54]), we did not find evidence for a stable ring-fraction of SAS-6 in solution, but found a complex equilibrium of SAS-6 oligomers (ranging up to approximately SAS-6 hexamers) for the wild-type construct in the absence of PK9119, while the F257E mutant was a stable dimer under these conditions, in agreement with stable dimer formation through its coiled-coil domain. When the runs were repeated in the presence of PK9119, we saw a clear shift in the elution volume for the wild-type but not the F257E SAS-6 construct towards smaller molecular weights and a decrease in the analysed mass from MALS, demonstrating that PK9119 partially affects head-to-head dimerization. We also repeated this experiment with the equivalent constructs of zebrafish SAS-6 (Dr SAS-6^1--326^, wild-type and F131D) under similar conditions. The results showed that zebrafish SAS-6 oligomerization was also affected by the presence of PK9119, although to a lesser extent than *L. major* SAS-6 oligomerization ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). Thus, PK9119 appears to be a general inhibitor of SAS-6 oligomerization in vitro with some preference for the *L. major* variant, and represents a starting point for further screening of chemical analogs or fragment evolution.

Discussion {#s3}
==========

SAS-6 organizes the rotationally ninefold symmetric cartwheel ([@bib42]; [@bib32]; [@bib54]), an early assembly intermediate of centrioles that participates in establishing their symmetry and diameter ([@bib42]; [@bib8]; [@bib23]). Based on high-resolution structures of SAS-6 fragments and in silico modeling, detailed models of how SAS-6 self-associates to organize these cartwheels have been proposed ([@bib42]; [@bib32]; [@bib54]). However, these models have so far not been confirmed; EM studies with recombinant SAS-6 constructs were either of too low resolution ([@bib32]) or showed assemblies that were not ninefold symmetric ([@bib24]; [@bib54]). Furthermore, several studies found no evidence for complete ring-formation by recombinant SAS-6 in solution ([@bib24]; [@bib32]; [@bib54]). Thus, it has been unclear if and under what conditions SAS-6 is sufficient to assemble ninefold symmetric cartwheels and thereby assist in dictating centriole symmetry.

We were unable to detect cartwheel formation by recombinant *L. major* SAS-6 in solution, confirming these previous findings. However, we demonstrate that under high protein and precipitant concentrations, a *L. major* SAS-6 construct crystallized as ninefold symmetric rings with a diameter very similar to cartwheel hubs in vivo; this provides the first unambiguous experimental evidence that SAS-6 is able to form ninefold symmetric cartwheels on its own. Our results suggest that SAS-6 needs to be highly concentrated locally in order to be able to form cartwheels. Intriguingly, in vivo, SAS-6 is indeed highly enriched at the site of centriole formation ([@bib33]; [@bib52]; [@bib13]; [@bib7]; [@bib50]; [@bib37]). However, in vivo, SAS-6 assembly occurs in the context of other essential centriole duplication factors, some of which can be found in a complex with SAS-6 ([@bib51]; [@bib53]; [@bib38]). It is therefore likely that additional centriole proteins assist SAS-6 assembly, especially in light of the fact that several studies ([@bib24]; [@bib32]; [@bib54]), and our study presented here, have been unable to demonstrate efficient cartwheel assembly by SAS-6 in solution.

Why does SAS-6 not form cartwheels efficiently? The interaction interfaces that are critical for ring formation (i.e., the head-to-head dimer interface and the head-domain--coiled-coil interface) are both relatively small ([Figures 1, 2](#fig1 fig2){ref-type="fig"}; [@bib32]; [@bib54]). In solution, SAS-6 oligomers are therefore likely to show some 'wobble' that would make ring closure inefficient and assembled rings unstable. However, in our ring structure, both of these critical interfaces are similar in their orientations to those observed in the crystals of the Lm SAS-6^97--320^ F257E and the Lm SAS-6^97--274^ constructs that did not crystallize as rings ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). Thus, although clearly not occurring efficiently in solution, our data suggest that ninefold symmetric ring formation might correspond to a weakly favored SAS-6 conformation that needs to be stabilized. In our crystal structure, rings are stabilized by crystal packing interactions and, in vivo, probably by SAS-6 interacting proteins. This model could explain why SAS-6 is required for the faithful establishment of centriole symmetry, while not being the sole determinant of their ninefold symmetry in vivo ([@bib42]).

In basal bodies, cartwheels are stacked onto each other with a vertical distance between cartwheel hubs of ∼8 nm ([@bib26]). Although we observed a similar stacking in our cartwheel hub structure ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}), the corresponding distance was only ∼4 nm. Furthermore, although a comparable packing was previously observed in a crystal of the N-terminal head domain of zebrafish SAS-6 ([@bib54]), the underlying packing interactions are based on a non-conserved interface and are therefore unlikely to be of relevance in vivo. Recent EM tomograms of basal bodies from Trichonympha ([@bib26], [@bib27]) rather suggest that ring stacking in vivo is based on parallel interactions between the SAS-6 coiled-coil stalks and vertical interactions of SAS-6 associated components at the periphery of centriolar cartwheels.

Interestingly, we discovered a dimerization-impaired state of *Leishmania major* SAS-6 that could provide a potential regulatory mechanism for its assembly. In this state, residue Y215 blocks the hydrophobic pocket into which F257 from its homo-dimer partner binds. Mutating Y215 to lysine resulted in an apparent threefold increase in dimerization affinity as measured by analytical ultracentrifugation. If open and closed Y215 conformations are in equilibrium with each other, the dimerization affinity of the closed Y215 state in solution would be even lower than the measured value, since, in this case, ultracentrifugation analyses the association of a mixture of open and closed states. We speculate that a release of this closed SAS-6 state through either a regulatory protein or a direct phosphorylation of Y215 could provide a simple mechanism to trigger SAS-6 assembly locally by increasing the concentration of assembly efficient SAS-6. Should this mechanism indeed be used in vivo (which is currently unknown), it would probably be confined to the Trypanosomatids as other SAS-6 homologues appear not to have tyrosine/aromatic residues in the position equivalent to Y215 that could play an equivalent role.

Finally, as a proof-of-principle we show that oligomerization of SAS-6 can be inhibited by the small molecule PK9119 in vitro. The evolutionary conservation of the hydrophobic pocket involved in dimerization together with PK9119's relatively broad activity in inhibiting both *L. major* and (to a lesser extent) *D. rerio* SAS-6 could suggest that PK9119 targets this pocket. However, our NMR binding studies are most consistent with PK9119 binding adjacent to the head-to-head dimerization interface and thereby altering its structure subtly ([Figure 3B](#fig3){ref-type="fig"}). Confirming this notion, when we modeled the SAS-6--PK9119 complex with the HADDOCK software package (available at <http://haddock.science.uu.nl/services/HADDOCK/haddock.php)> ([@bib15]; [@bib56]), using high ambiguity restraints derived from the observed chemical shift perturbations in HSQC spectra (6 restraints \>0.2 ppm), we found that of the 200 docked structures 98% occupied a single cluster in which PK9119 was bound to helix α1, but not on the side lining the hydrophobic pocket, but on its opposite side, facing away from this pocket (data not shown). Clearly, an elucidation of a high-resolution structure of PK9119 bound to its target would be important to understand how exactly PK9119 functions in inhibiting *L. major* SAS-6. The binding affinity of our compound is currently low (in the mM range) and it does not show strong species specificity. To establish whether PK9119 has any potential to be improved in these critical aspects, it will be essential to systematically explore chemical modifications of its central indole scaffold. Regardless of these limitations, our demonstration that SAS-6 can be inhibited in vitro is a first, small step towards the goal of developing SAS-6 inhibitors that also could be used in vivo, for example as a cell-biological tool.

Materials and methods {#s4}
=====================

Recombinant protein expression and purification {#s4-1}
-----------------------------------------------

All *L. major* constructs were made synthetically as codon-optimized genes (IDT, Coralville, Iowa). Zebrafish SAS-6 constructs were described earlier ([@bib54]). All constructs were N-terminally His-tagged. Proteins were expressed in *E. coli* BL21 Rosetta and purified using standard methods via NiNTA (Qiagen, Hilden, Germany) chromatography, proteolytic tag cleavage, size-exclusion chromatography and ion-exchange chromatography. The *L. major* SAS-6^97--274^ and SAS-6^97--320^ selenomethionine derivatives were purified in the same way, but expression was in M9 medium supplemented with 2 mM MgSO~4~, 0.4% (wt/vol) glucose, 25 µg/ml FeSO~4~.7H~2~O, 40 µg/ml amino acid mix (excluding Methionine), 1 µg/ml riboflavin, 1 µg/ml niacinamide, 0.1 µg/ml pyridoxine monohydrochloride, 1 µg/ml thiamine and 40 µg/ml seleno-L-methionine. All purified *L. major* constructs included the extra sequence GP, zebrafish SAS-6 GPH at their N-termini from the cloning/protease cleavage site.

Crystallization {#s4-2}
---------------

SeMet *L. major* SAS-6^97--274^ crystals were obtained using the sitting drop method with a reservoir solution of 100 mM bisTris pH 5.1, 200 mM MgCl~2~, 20% (wt/vol) PEG-3350 at 16°C. Drops were set up using 100 nl protein solution and 100 nl of reservoir solution. After half a day, the crystals were mounted in 100 mM bisTris pH 5.1, 200 mM MgCl~2~, 10% (wt/vol) PEG-3350, 25% (wt/vol) Glycerol and flash-frozen in liquid nitrogen.

Native *L. major* SAS-6^97--274^ was crystallized at 16°C using the sitting drop method with 200 nl of the protein solution and 200 nl of the reservoir solution (100 mM bisTris pH 5.1, 200 mM MgCl~2~, 20% \[wt/vol\] PEG-3350). The crystals were mounted in 100 mM bisTris pH 5.1, 200 mM MgCl~2~, 10% (wt/vol) PEG-3350, 25% (wt/vol) glycerol after 1 day and flash-frozen in liquid nitrogen.

*L. major* SAS-6^97--320^ F257E was crystallized in sitting drops in 100 mM NaCitrate pH 5.85, 21% (wt/vol) PEG-3000 at 16°C using 1 μl of protein solution and 1 μl of the reservoir solution. The crystals were mounted after 4--5 days in 100 mM NaCitrate pH 5.85, 21% (wt/vol) PEG-3000 and increasing amounts of PEG-400 to a final concentration of 20% (wt/vol) before flash-freezing them in liquid nitrogen.

*L. major* SAS-6^97--320^ WT crystals were obtained using the sitting drop method with a reservoir solution of 100 mM bisTris pH 6.23, 100 mM NaAcetate (not pH adjusted), 26.5--27% (wt/vol) PEG-400 at 16°C. Drops were set up using 1.8 μl of protein solution and 1.8 μl of the reservoir solution. After 3 days, the crystals were mounted in 100 mM bisTris pH 6.23, 100 mM NaAcetate (not pH adjusted), 28% (wt/vol) PEG-400.

SeMet *L. major* SAS-6^97--320^ WT crystals were obtained using the sitting drop method with a reservoir solution of 100 mM bisTris pH 6.23, 100 mM NaAcetate (not pH adjusted), 25.5% (wt/vol) PEG-400 at 16°C. Drops were set up using 1.5 μl of protein solution and 1.5 μl of the reservoir solution. After 3 days, the crystals were mounted in 100 mM bisTris pH 6.23, 100 mM NaAcetate (not pH adjusted), 30% (wt/vol) PEG-400.

The protein concentrations of the crystallized constructs were determined by the Bradford assay with BSA as a standard and were: 80.3 mg/ml (SeMet *L. major* SAS-6^97--274^), 29.3 mg/ml (*L. major* SAS-6^97--274^), 94.7 mg/ml (*L. major* SAS-6^97--320^ F257E), 50.3 mg/ml SeMet *L. major* SAS-6^97--320^ and 50.1 mg/ml (*L. major* SAS-6^97--320^).

Data collection and processing {#s4-3}
------------------------------

Data sets were integrated and scaled using MOSFLM ([@bib36]) (SeMet and native *L. major* SAS-6^97--274^, *L. major* SAS-6^97--320^) or XDS ([@bib31]) (*L. major* SAS-6^97--320^ F257E and SeMet *L. major* SAS-6^97--320^). Data sets were scaled using SCALA or AIMLESS ([@bib18]; [@bib19]). The *L. major* SAS-6^97--274^ structure was solved from the corresponding 3-wavelength SeMet dataset by MAD using the SHELX CDE pipeline in HKL2MAP ([@bib45]), resulting in clear electron density into which an initial model was built using BUCANNEER ([@bib11], [@bib12]) and manual building. REFMAC ([@bib41]) was used to refine the model against the native data set with manual building done in Coot ([@bib17]). *L. major* SAS-6^97--320^ WT and F257E were solved by molecular replacement in Phaser ([@bib39]) using the *L. major* SAS-6^97--274^ structure as a search model (SAS-6^97--274^ monomer (F257E) or the BC-dimer (WT). The models were subsequently further built in Coot ([@bib17]) and refined in REFMAC ([@bib41]) and Phenix.refine ([@bib1]) using NCS and (for WT *L. major* SAS-6^97--320^) TLS refinement with separate TLS groups for the globular N-terminal and the coiled-coil domains and also using as a reference model restraint the B chain of *L. major* SAS-6^97--274^ (residue 130--271). Refinement yielded clear density for the missing coiled-coil part of these constructs.

Analytical ultracentrifugation {#s4-4}
------------------------------

Equilibrium sedimentation experiments were performed on an Optima XL-I analytical ultracentrifuge (Beckmann, Brea, California) using An50Ti rotors. Sample volumes of 110 µl with protein concentrations of 100, 200, and 400 μM were loaded in 12 mm 6-sector cells and centrifuged at 11300, 17000, and 21200 rpm until equilibrium was reached at 4°C. At each speed, comparison of several scans was used to judge whether or not equilibrium had been reached. Buffer conditions were 50 mM Tris, 100 mM NaCl, pH 8.0. The solvent density and viscosity (ρ = 1.00557 g/ml and η = 1.6056 mPa⋅s) were calculated using Sednterp (Dr Thomas Laue, University of New Hampshire, Sednterp server available at: <http://sednterp.unh.edu>. Desktop version can be downloaded from: <http://bitcwiki.sr.unh.edu/index.php/Downloads>). Data were processed and analysed using UltraSpin software (available at: <http://www.mrc-lmb.cam.ac.uk/dbv/ultraspin2/>) and SEDPHAT ([@bib47]).

NMR experiments {#s4-5}
---------------

Small molecules were screened for binding to approximately 40 µM ^15^N-labelled protein in aqueous phosphate buffer (25 mM Phosphate, 150 mM NaCl, 2 mM DTT, pH 7.2) and up to 2 mM ligand concentration, with a total of 5% (vol/vol) DMSO-*d*~6~. {^1^H-^15^N}-fast-HSQC spectra ([@bib40]) were recorded using a Bruker Avance spectrometer operating at 800 MHz ^1^H frequency, with a 5 mm cryogenic inverse probe and sample temperature of 298 K. The digital resolution of the processed data was 3.2 and 5.3 Hz/point in *f*~2~ and *f*~1~, respectively. Backbone resonance assignments were obtained from HNCACB, CBCA(CO)NH, HN(CA)CO, HNCO and HNCANH spectra at 600 MHz ^1^H frequency, acquired using unmodified Bruker pulse programs and a protein concentration of 400 µM. Aromatic sidechain resonances were assigned from a (HB)CB(CGCD)HD spectrum. Data were processed using TopSpin version 3 (commercially available from Bruker, Billerica, Massachusetts, details available at <http://www.bruker.com/products/mr/nmr/nmr-software/software/topspin/>) and analysed using Sparky (Goddard & Kneller, UCSF, San Francisco, available at <http://www.cgl.ucsf.edu/home/sparky/>).

HADDOCK calculations {#s4-6}
--------------------

Models of the complex between SAS-6 and PK9119 were generated by submitting the crystal structure coordinates of a *L. major* SAS-6^97--274^ monomer to the WeNMR server (available at: <https://www.wenmr.eu>) ([@bib15]; [@bib56]), using default HADDOCK parameters and CNS topology parameters for PK9119 based on the PRODRG predictions provided on the HADDOCK server (available at <http://haddock.science.uu.nl/services/HADDOCK/haddock.php>).

Size exclusion chromatography coupled to multi-angle light scattering (SEC-MALS) {#s4-7}
--------------------------------------------------------------------------------

The mass in solution of *L. major* SAS-6^97--424^, wild-type and F257E mutant, Dr SAS-6^1−326^, wild-type and F131D mutant, was determined by SEC-MALS measurements using a Wyatt Heleos II 18 angle light scattering instrument coupled to a Wyatt Optilab rEX online refractive index detector. Detector 12 in the Heleos instrument was replaced with Wyatt's QELS detector for dynamic light scattering measurement. Protein samples (100 μl) were resolved on a Superdex S-200 10/300 analytical gel filtration column (GE Healthcare, Little Chalfont, UK) running at 0.5 ml/min in 50 mM bisTris, 100 mM NaCl, pH 7.0 buffer, containing 0.126% (vol/vol) DMSO and ±1 mM chemical compound PK9119 ((5-bromo-7-ethyl-1H-indol-3-ylmethyl)-dimethyl-amine, Sigma-Aldrich, St. Louis, Missouri) before passing through the light scattering and refractive index detectors in a standard SEC-MALS format. Buffers were filtered through a 0.22-μm filter before usage to remove any PK9119 precipitates. Protein concentration was determined from the excess differential refractive index based on 0.186 RI increment for 1 g/ml protein solution. The concentration and the observed scattered intensity at each point in the chromatograms were used to calculate the absolute molecular mass from the intercept of the Debye plot using Zimm's model as implemented in Wyatt's ASTRA software (commercially available from Wyatt technology, Santa Barbara, California, details at: <http://www.wyatt.com/products/software/astra.html>).
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Thank you for sending your work entitled "Structure of the SAS-6 cartwheel hub from *Leishmania major*" for consideration at *eLife*. Your article has been favorably evaluated by a Senior editor, John Kuriyan, and 3 reviewers, one of whom, Erich Nigg, has agreed to reveal his identity.

The Senior editor and reviewers discussed their comments before we reached this decision, and the Senior editor has assembled the following comments to help you prepare a revised submission.

The centriolar protein SAS-6 has recently been shown to be a major determinant of the 9-fold symmetry of the cartwheel, an important structure in centriole assembly. (This was shown independently by two groups, one being the author of the present study). This conclusion was based on a combination of X-ray structure data, in silico modeling and rotatory shadowing EM. Although immediately embraced by the community as an important and beautiful advance, it had not previously been established formally that SAS-6 alone can assemble into rings with 9-fold symmetry.

The gap in structural knowledge concerning SAS-6 has been filled in the present study. Structures of fragments containing the N-terminal head domain (97-274) or a dimerization deficient head domain + coiled coil fragment (97-320 F237E) provide new insights into the interactions that stabilize head-to-head SAS-6 dimer interfaces and the interface between the coiled-coil and the head domain, respectively. Most importantly, the authors were also able to solve the structure of the wild-type 97-320 construct, and made the important observation that this fragment crystallizes in a nine-fold symmetry, creating a ring with a diameter very similar to cartwheel hubs observed in centrioles in vivo. Thus, the authors\' data show that SAS-6 is sufficient to form a ring with nine-fold symmetry and that other components are not required.

The authors also provide evidence for a potential auto-inhibitory conformation in *Leishmania* SAS-6 (involving Y215) -- however, this aromatic residue is not present in animal SAS-6 and its in vivo relevance is uncertain. In addition, the manuscript identifies a pocket at a dimer interface between head domains that can be targeted by small molecules. Although they emphasize the potential of future therapeutic uses of such compounds, the present data are rather preliminary and can only be seen as a first modest step in this direction (the compound is of low affinity and shows little species-specificity).

In conclusion, that the authors have determined a crystal structure of the cartwheel is really quite remarkable, given its large diameter and the lack of stabilizing internal spokes. The additional structures add to the strength of the story. The identification of a potential small molecule inhibitor is nice and makes it a sound story for publication. The auto-inhibitory discussion may be a little overdone with little experimental support, but it seems reasonable to present the idea that Y215 may play a direct role in SAS-6 assembly regulation. Thus, the paper should be published in *eLife* once the authors have addressed the following minor comments, using their own judgement as to how best to respond to each of these points. The revised paper will receive a very rapid final decision by the editor without further review, and so a clear discussion of how these points are addressed will be helpful.

Minor comments:

1\) The authors state that SAS-6 rings are stacked onto each other in the crystal and they also refer to literature stating that Sas-6 rings are stacked onto each other in basal bodies ([@bib26]). They should discuss these data, and also a recent publication reporting that *C. elegans* SAS-6 forms a spiral (Hilbert et al., PNAS 2013).

2\) A couple of the reviewers had issues related to arguments about energy.

The full architecture could be more stable than intermediates; however, if it were low energy than it would be favored in solution, which it is not. It is also clear that it isn\'t stable in any in vitro context outside the crystal. Since it is difficult to argue about free energy or energy from crystal structures, particularly due to the confounding effects of local concentration, the authors may wish to just exclude these arguments (the structure speaks for itself). Specifically, in the section entitled '*Leishmania major* SAS-6 crystallizes as 9-fold symmetric rings that are highly similar to centriolar cartwheels in vivo': the authors argue that because each of the dimers in the asymmetric unit in the 97-320 structure has a similar conformation, this conformation represents a low energy state of SAS-6. The logic of this argument and the rationale for making it are unclear. Any conformation that crystallizes (including tetrameric and octameric SAS-6) is likely to be a low energy conformation. The observation that under the 97-320 crystallization conditions SAS-6 forms a nine-membered ring is not sufficient evidence to claim the head-to-head dimer conformation in the nine-fold symmetrical ring is more stable in general than the dimer interfaces previously observed in octameric or tetrameric structures.

3\) The authors state in the Abstract that their data indicate how cartwheel assembly is regulated in vivo. While the observation that a residue in Lm SAS-6 can adopt a conformation that weakens head-to-head contacts is suggestive, it is premature to state that this observation provides the structural basis for regulation of cartwheel-imposed symmetry.

4\) Section entitled 'A small compound can inhibit SAS-6 oligomerization in vitro': The NMR data show perturbations in and around the hydrophobic dimerization pocket when the inhibitor binds. It would be easier to assess the correlation between the chemical shift data and the residues in the dimerization pocket if the authors explicitly listed the residues (and ideally, show them in the figure) that are within interaction distance of F527 versus those that show a perturbation. Because of the sensitivity of chemical shift perturbations to allosteric structural changes, the authors should consider modifying the statement "Strong perturbations indicate that PK9119 ... binds" to indicate that the perturbation data is consistent with PK9119 binding to the hydrophobic pocket.

5\) Discussion section: The authors observe that the nine-membered rings stack vertically in the crystal based on interactions between the head domains, with a stacking distance of about 4 nm. That the ring stacking distance is much greater in vivo and that the stacking interfaces in the crystal are not conserved argues against the authors\' speculation that the observed ring stacking contacts in the crystal are important during cartwheel assembly. It would be an improvement to remove this speculation.

6\) Last paragraph of Discussion section: The authors note that PK9119 can be docked into the hydrophobic pocket. The authors do not present criteria for evaluating whether a particular ligand can be docked or not. Therefore, the authors should either include the docking data in the Results section, making the details of the modeling and it\'s interpretation clear, or this statement should be removed from the Discussion.

7\) Results section" The term \'helix-turn-helix motif\' is defined as an architecture in certain DNA binding proteins. I found the use of the phrase here inappropriate. If it truly is a helix-turn-helix motif it should be explained better.

8\) The description of the B-C homo-dimer is not symmetry related, unless there is a misunderstanding. This is an asymmetric unit dimer while the A-A homo-dimer is symmetry related. It should be clarified. The use of color in [Figure 1](#fig1){ref-type="fig"} is confusing as the molecules are colored the same even though different interfaces are being described. Altering the color to make these more distinct would be helpful. Specifically, using different colors for the subunit interfaces would help in clarity as one relates the complexes to each other. Minimally, flipping the coloring in E would make it easier to understand how the dimerization interfaces differ. This could then be echoed in [Figure 2](#fig2){ref-type="fig"}. Adding numbers to D would help more than these traces.

9\) Section entitled 'Alternative dimerization arrangements of *Leishmania major* SAS-6 suggest an auto-inhibitory mechanism': This is where the auto-inhibitory discussion becomes confusing. Auto-inhibitory suggests that there must be a state change to get binding. Instead, what is described is that the conformation of Y215 lowers the affinity but doesn\'t inhibit binding. This can be described better.

10\) "This map showed a good agreement\..." is strange phrasing. Did the methionine positions agree with the anomalous map? If so, it should just say \'Peaks in this map correlated to positions of methionines in our model.\'

11\) Discussion section: The argument that concentration mediates cartwheel formation seems overstated. As the assembly process requires other proteins, it seems more likely that other proteins convey stability to form the complex.

12\) Last paragraph of Discussion section: If the authors would like to discuss PK9119 docking they should describe this in more detail in the results. The methods do not give enough details to suggest that there is any reason to trust the results. This should be either dropped or expanded.

13\) Regarding the docking, the argument that \'our results suggest that targeting SAS-6 oligomerization\...to interfere with pathogenicity\' may be a bit too strong. Clearly, others have demonstrated oligomerization of SAS-6 homologues is critical in centriole formation and flagella are important in tyrpanosomatids, so the idea is not a novel one. That said, the authors should more strongly state that they have demonstrated that a small molecule can affect this assembly in vitro. However, that is a long way from showing that this interface will be a good target in vivo, moreover, it isn\'t obvious that they have identified a great lead compound for this.

10.7554/eLife.01812.016

Author response

*1) The authors state that SAS-6 rings are stacked onto each other in the crystal and they also refer to literature stating that Sas-6 rings are stacked onto each other in basal bodies (*[@bib26]*). They should discuss these data, and also a recent publication reporting that C. elegans SAS-6 forms a spiral (Hilbert et al., PNAS 2013)*.

And

*5) Discussion section: The authors observe that the nine-membered rings stack vertically in the crystal based on interactions between the head domains, with a stacking distance of about 4 nm. That the ring stacking distance is much greater* in vivo *and that the stacking interfaces in the crystal are not conserved argues against the authors\' speculation that the observed ring stacking contacts in the crystal are important during cartwheel assembly. It would be an improvement to remove this speculation*.

We agree that our speculation that the ring stacking observed in the crystal might serve in vivo to facilitate/template further ring formation might be seen as too far stretched. Although we had clearly discussed the shortcomings of this hypothesis previously, we now completely rewrote this part of the discussion to point out that the observed ring stacking is probably not relevant in vivo. We also further expanded our discussion of how ring stacking might be mediated in vivo in light of the recent EM tomographic reconstructions of basal bodies. Concerning the Hilbert et al., (PNAS 2013) publication reporting that *C. elegans* SAS-6 might form 9-fold symmetric spirals we preferred not to expand the Discussion (which is already long) further. Although Hilbert et al.'s data demonstrate that SAS-6 self-assembly could also be compatible with a different organization (spiral vs ring) Hilbert et al show that this would be a nematode-specific phenomenon since a nematode-specific residue sterically makes ring-formation in *C. elegans* unlikely. So far, SAS-6 spirals have not been demonstrated in *C. elegans* in vivo and we therefore believe that tying in their findings in our discussion would not be straightforward and would run the risk of distracting from the "canonical" SAS-6 homologues with well-established cartwheel geometries.

*2) A couple of the reviewers had issues related to arguments about energy*.

*The full architecture could be more stable than intermediates; however, if it were low energy than it would be favored in solution, which it is not. It is also clear that it isn\'t stable in any* in vitro *context outside the crystal. Since it is difficult to argue about free energy or energy from crystal structures, particularly due to the confounding effects of local concentration, the authors may wish to just exclude these arguments (the structure speaks for itself). Specifically, in the section entitled 'Leishmania major SAS-6 crystallizes as 9-fold symmetric rings that are highly similar to centriolar cartwheels* in vivo*': the authors argue that because each of the dimers in the asymmetric unit in the 97-320 structure has a similar conformation, this conformation represents a low energy state of SAS-6. The logic of this argument and the rationale for making it are unclear. Any conformation that crystallizes (including tetrameric and octameric SAS-6) is likely to be a low energy conformation. The observation that under the 97-320 crystallization conditions SAS-6 forms a nine-membered ring is not sufficient evidence to claim the head-to-head dimer conformation in the nine-fold symmetrical ring is more stable in general than the dimer interfaces previously observed in octameric or tetrameric structures*.

We have been unclear in our argument and therefore corrected the corresponding sections of our manuscript. However, we maintain that the nine-membered ring might correspond to a weakly favored conformation. We show now with a supplementary figure ([Figure 2--figure supplement 2](#fig2s2){ref-type="fig"}) that the head-to-head orientation and the relative orientation of head-domains to coiled coil stalks in the nine-membered ring are similar to those observed in the two other crystal structures presented in our manuscript that do not crystallize as rings (97-320 FE construct and WT 97-274 construct). Furthermore, in previous studies, in silico modeling of 9-fold symmetric rings required only small changes of the crystal structures of zebrafish and *Chlamydomonas* SAS-6 fragments (van Breugel M et al. Science. 2011; 331(6021):1196-9, Kitagawa et al. Cell. 2011; 144(3):364-375). To our mind these data suggest that despite some "wobble", due to the small interaction interfaces involved, the observed orientations in our ring structure might very well be weakly favored. Efficient ring-formation is clearly not observed in solution, probably due to this flexibility and also due to the low affinities involved. Under our assay conditions (SEC-MALS) it would be difficult to observe a small fraction of nine-fold symmetric rings present in solution. We argue that SAS-6 rings need to be stabilized, either by crystal packing interactions (as in our structure in vitro) or by additional SAS-6 interacting proteins (in vivo). We believe that this model could explain why SAS-6 is essential for faithful establishment of the centriolar symmetry, while not being the sole determinant of it. We discuss this now in detail in our manuscript.

*3) The authors state in the Abstract that their data indicate how cartwheel assembly is regulated* in vivo*. While the observation that a residue in Lm SAS-6 can adopt a conformation that weakens head-to-head contacts is suggestive, it is premature to state that this observation provides the structural basis for regulation of cartwheel-imposed symmetry*.

In our manuscript we previously made it clear that it is entirely unknown whether this mechanism is indeed used in vivo or not. Since we want to avoid any misunderstanding we further weakened or removed corresponding statements in our manuscript.

*4) Section entitled 'A small compound can inhibit SAS-6 oligomerization* in vitro*': The NMR data show perturbations in and around the hydrophobic dimerization pocket when the inhibitor binds. It would be easier to assess the correlation between the chemical shift data and the residues in the dimerization pocket if the authors explicitly listed the residues (and ideally, show them in the figure) that are within interaction distance of F527 versus those that show a perturbation. Because of the sensitivity of chemical shift perturbations to allosteric structural changes, the authors should consider modifying the statement "Strong perturbations indicate that PK9119 ... binds" to indicate that the perturbation data is consistent with PK9119 binding to the hydrophobic pocket*.

And

*6) Last paragraph of Discussion section: The authors note that PK9119 can be docked into the hydrophobic pocket. The authors do not present criteria for evaluating whether a particular ligand can be docked or not. Therefore, the authors should either include the docking data in the Results section, making the details of the modeling and it\'s interpretation clear, or this statement should be removed from the Discussion*.

And

*12) Last paragraph of Discussion section: If the authors would like to discuss PK9119 docking they should describe this in more detail in the results. The methods do not give enough details to suggest that there is any reason to trust the results. This should be either dropped or expanded*.

Our NMR data ([Figure 3C](#fig3){ref-type="fig"}) show that PK9119 causes the largest shift perturbations in helix α1 that lines the hydrophobic pocket where F257 is normally inserted. However, the extent of the perturbations are largest on the outside of this helix not the side facing the pocket, which can be clearly evaluated from [Figure 3C](#fig3){ref-type="fig"}. Furthermore, we looked at aromatic side chain 1H resonances of Phe and Tyr residues using Cβ-Hδ correlation maps, and found that F199, F212 (both lining the hydrophobic pocket) are perturbed on binding of PK9119 ([Figure 3--figure supplement 1](#fig3s1){ref-type="fig"}). Together, the NMR data therefore would probably be most consistent with PK9119 binding outside of the hydrophobic pocket in a cleft on the other side of the hydrophobic pocket divider, although interpretations are difficult due to sidechain reorganisation and other conformational changes that can contribute to shift perturbation. We had tried to be clear in our manuscript that PK9119 likely binds around (or in) the hydrophobic pocket. PK9119 docking/binding to the pocket was only mentioned in the Discussion as a possibility.

The reviewers' comments made us realize that we need to clarify these issues further. We modeled the complex between SAS-6 and PK9119 using the HADDOCK docking package, applying restraints derived from the observed chemical shift perturbations. We found that, indeed, the ligand consistently docks close to helix α1, but not on the side lining the hydrophobic pocket, but on its opposite side, facing away from this pocket. However, since there is considerable variation in the binding mode of the ligand in the 200 trial structures, we have preferred not to include an image of the HADDOCK output that might be misconstrued as representing a true solution structure. Thus, in our revised manuscript, we now do not include any docking figure, as this would distract from the NMR data. Furthermore, we clarified each statement in the manuscript that refers to the potential PK9119 binding site to reflect what is discussed here.

*7) Results section" The term \'helix-turn-helix motif\' is defined as an architecture in certain DNA binding proteins. I found the use of the phrase here inappropriate. If it truly is a helix-turn-helix motif it should be explained better*.

The helix-turn-helix motif is a functionally divergent motif that in some proteins has lost the DNA binding function and acquired other functions such as protein-protein interaction for instance (Aravind L et al., FEMS Microbiol Rev. 2005 Apr;29(2):231-62.). XLF and XRCC4, the structural homologues of SAS-6 that are involved in DNA repair, both have helix-turn-helix motifs (Junop MS et al. EMBO J. 2000 Nov 15;19(22):5962-70. Li Y et al. EMBO J. 2008 Jan 9;27(1):290-300.) similar to SAS-6's (van Breugel M et al. Science. 2011 Mar 4;331(6021):1196-9) (it is at this stage uncertain whether the HTH motifs of XRCC4 and XLF have a role in DNA binding). Thus, it seems to be appropriate to call the equivalent motif in SAS-6 a helix-turn-helix motif. As SAS-6 is not involved in DNA binding, we furthermore believe that it will not be confusing to leave the corresponding passages as they are.

*8) The description of the B-C homo-dimer is not symmetry related, unless there is a misunderstanding. This is an asymmetric unit dimer while the A-A homo-dimer is symmetry related. It should be clarified. The use of color in* [*Figure 1*](#fig1){ref-type="fig"} *is confusing as the molecules are colored the same even though different interfaces are being described. Altering the color to make these more distinct would be helpful. Specifically, using different colors for the subunit interfaces would help in clarity as one relates the complexes to each other. Minimally, flipping the coloring in E would make it easier to understand how the dimerization interfaces differ. This could then be echoed in* [*Figure 2*](#fig2){ref-type="fig"}*. Adding numbers to D would help more than these traces*.

We reformatted the ASU to avoid the misunderstanding and changed the corresponding descriptions. We flipped the colors of the subunits in [Figure 1E](#fig1){ref-type="fig"} to facilitate the appreciation of how SAS-6 oligomerization occurs and kept this coloring scheme also in [Figure 2](#fig2){ref-type="fig"} to make the two figures color-wise directly comparable. Concerning the ultracentrifugation panel, we added the K~D~'s to [Figure 1D](#fig1){ref-type="fig"}, but also kept the traces as we believe it is good to see the quality of the fit.

*9) Section entitled 'Alternative dimerization arrangements of Leishmania major SAS-6 suggest an auto-inhibitory mechanism': This is where the auto-inhibitory discussion becomes confusing. Auto-inhibitory suggests that there must be a state change to get binding. Instead, what is described is that the conformation of Y215 lowers the affinity but doesn\'t inhibit binding. This can be described better*.

It is not clear to us that auto-inhibition as a term must necessarily be limited to a state of complete self-inhibition. Furthermore, it is unclear to what extent the closed conformation inhibits oligomerization. Since open and closed state are likely to be in equilibrium with each other (change of state requires only a rotamer change of Y215) we measure in ultracentrifugation a mixture of these states and thus end up with an "average" K~D~. Depending where the equilibrium lies it is thus very well possible that the closed state has a very low ability to dimerize in solution. In agreement, the F257E mutant oligomerizes in the closed state but only in the crystal and not in solution arguing that the remaining contact interface indeed mediates only a very weak interaction. Nevertheless, at this stage we are unable to directly demonstrate the K~D~ of the closed state alone. Furthermore, at least in the crystal, the closed state is indeed still able to oligomerize, potentially leading to misunderstandings. Thus, we follow the advide of the reviewers, avoid calling it auto-inihibition, and describe/discuss this part of our manuscript better and in more detail making all these points clearer.

*10) "This map showed a good agreement\..." is strange phrasing. Did the methionine positions agree with the anomalous map? If so, it should just say \'Peaks in this map correlated to positions of methionines in our model.*\'

The methionine positions agree very well with the anomalous map (see [Figure 2B](#fig2){ref-type="fig"}) and we corrected our phrasing as suggested.

*11) Discussion section: The argument that concentration mediates cartwheel formation seems overstated. As the assembly process requires other proteins, it seems more likely that other proteins convey stability to form the complex*.

We do not think that one argument excludes the other. Our data suggest that SAS-6 can -- under high concentrations -- form 9-fold symmetric rings and the published data suggest that SAS-6 is indeed highly enriched at the place of centriole duplication. However, SAS-6 ring formation clearly requires stabilization, either by crystal packing interactions (in vitro) or by other SAS-6 interacting proteins (in vivo). Thus, we argue that centriole assembly needs both high SAS-6 concentrations and SAS-6 interacting proteins that stabilize a 9-fold symmetric assembly. We further clarified our discussion of this point in our manuscript.

*13) Regarding the docking, the argument that \'our results suggest that targeting SAS-6 oligomerization\...to interfere with pathogenicity\' may be a bit too strong. Clearly, others have demonstrated oligomerization of SAS-6 homologues is critical in centriole formation and flagella are important in tyrpanosomatids, so the idea is not a novel one. That said, the authors should more strongly state that they have demonstrated that a small molecule can affect this assembly* in vitro*. However, that is a long way from showing that this interface will be a good target* in vivo*, moreover, it isn\'t obvious that they have identified a great lead compound for this*.

By no means do we want to get across as having identified a great lead or that SAS-6 is necessarily a fantastic target for inhibition by small molecules in vivo. In fact, we were very careful in clearly emphasizing the shortcomings of the compound both in terms of affinity as well as in terms of species specificity (and solubility). As the reviewers pointed out, what we achieved is only a proof-of-principle that SAS-6 oligomerisation can be inhibited in vitro by a small molecule. Thus, we changed/toned down further all parts of the manuscript where there still might be misunderstandings about these points.

[^1]: Novartis Institutes for BioMedical Research, Basel, Switzerland.
